Replies to post #162337 on Cytodyn Inc (CYDY)

[DonDonDonDon]

The trials were poorly designed because CYDY's management is incompetent. The drug works but Nader and Kelly are terrible managers.

Also, my children knew the difference between "there", "they're", and "their" when they were in elementary school. If you want to be taken seriously, I'd suggest you learn the difference.

People who have nothing of substance to say are often reduced to critiquing grammar or spelling.

The trials failed. Give all the excuses you want. You had some slightly good data on a 62 patient slice. That good data is more than likely the result of random luck.

Why do you think leronlimab failed so badly with severe patients?

[Evil Rabbit]

Amazing how patients die when you stop giving them medicine. After day 17, Leronlimab would have been fading from the CD12 patients’ system.

Good job FDA wouldn’t let those patients get two more doses. Couldn’t have them live and crush the PE, could we...

[tikotiko]

I agree. There is no doubt that the outstanding 82% efficacy by day 14 would have translated into similar numbers by day 28 with weekly doses. Unfortunately, that did not happen because of the reasons you presented and the many FDA’s games. This should be evident to any person with basic common sense and logic. Big Pharma companies are even more aware of this fact and of the possible extrapolations with weekly doses. I am convinced that they are watching closely. Nader should consider doing the US COVID trial with a BP partner to either split profits or consider a buyout. This could be somewhat similar to what RLFTF was planning to do with Redemsideath. At the same time, the international efforts should continue. The opportunity is now, but I am not sure if Nader’s stubbornness may get in the way. Regardless, I am holding long, because I know this therapeutic is better than anything else in the market, including the HGEN drug, which I also happen to own. The Leronlimab molecule is way too valuable and the big fish know it.

[C-20]

Mercurio- great post as you absolutely nailed it , the problem is not with our drug and even with the poor trial design it still outperformed anything else in this phase of covid.